doi: 10.1159/000330447 74 HegedsLShermanSITuttleRMvon ScholtenBJRasmussenSKarsblJDet al
potential FDA submission 2028 (estimated): Possible FDA approval and commercial availability In the meantime, FDA-approved weight loss medications are available now
Note: Medication is only prescribed when clinically appropriate
Exenatide, an exogenous GLP-1RA, has been shown to enhance hypothalamic connectivity in obese individuals who respond to its anorexigenic effects, while also decreasing food reward-related brain activation
Drug-device combination products, such as prefilled syringes (PFSs), autoinjectors and other drug delivery systems, have evolved to meet this demand
Medical Safety Issues Using retatrutide without medical supervision means: No monitoring for side effects or complications Inappropriate dosing without medical guidance Drug interactions that go undetected Emergency situations without proper medical support FDA-Approved Alternatives to Consider While waiting for potential retatrutide approval, several FDA-approved weight loss medications are available through legitimate medical channels: GLP-1 Receptor Agonists These medications work similarly to one component of retatrutides triple action: Semaglutide (Ozempic for diabetes and Wegovy for weight loss) Tirzepatide (GLP-1/GIP receptor agonist sold as Mounjaro for diabetes and Zepbound for weight loss) Liraglutide (Victoza for diabetes and Saxenda for weight loss) Orforglipron (Foundayo) Other Prescription Options Additional FDA-approved weight loss medications include: These medications require prescriptions from licensed healthcare providers who can properly evaluate your eligibility and monitor your progress
